


## PHARMACEUTICAL 2018



## IntelGenx Technologies Corp. Rank 117 of 349





## PHARMACEUTICAL 2018



## IntelGenx Technologies Corp. Rank 117 of 349

The relative strengths and weaknesses of IntelGenx Technologies Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IntelGenx Technologies Corp. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 175% points. The greatest weakness of IntelGenx Technologies Corp. is the variable Assets, Current, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is -66%, being 212% points above the market average of -278%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 6,044             |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 2,077             |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 757               |
| Other Compr. Net Income                     | 382               |
| Other Expenses                              | 1,677             |
| Other Liabilities                           | 7,241             |
| Other Net Income                            | 11                |
| Property and Equipment                      | 6,346             |
| Research and Development                    | 2,615             |
| Revenues                                    | 5,195             |
| Selling, General and Administrative Expense | 3,965             |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 13,147            |
| Liabilities              | 9,318             |
| Expenses                 | 8,257             |
| Stockholders Equity      | 3,829             |
| Net Income               | -3,051            |
| Comprehensive Net Income | -2,860            |
| Economic Capital Ratio   | -66%              |